[Effect of transcatheter arterial chemoembolization on HBV DNA level in primary liver cancer patients].
OBJECTIVE
Systemic chemotherapy would suppress the immune system and cause reactivation of hepatitis B virus (HBV) in the tumor patients with HBV infection, which seriously affect the prognosis. Our study was to investigate the effect of transcatheter arterial chemoembolization (TACE) on HBV DNA level in primary liver cancer patients, and explore related factors.


METHODS
Clinical data of 162 patients with primary liver cancer who underwent TACE from December 2004 to July 2008 were analyzed. All patients' HBV DNA level, alpha-fetoprotein (AFP) and liver function before and after TACE were evaluated. Correlation of HBV DNA alteration to AFP was analyzed.


RESULTS
The positive rate of HBV DNA was decreased significantly after TACE (55.6% vs. 71.6%, P<0.01). HBV DNA level was inclined to decrease after TACE in the patients with HBV DNA of > or =1 x 10(5)/mL (odds ratio = 2.7, P<0.01). The decrease of HBV DNA was also related with the decrease of AFP level (odds ratio = 2.6,P<0.05).


CONCLUSIONS
TACE can decrease HBV DNA level in primary liver cancer patients, especially for those with preoperative HBV DNA level of > or =1 x 10(5)/mL and those with postoperative AFP decline.
Xu
Jing
J
Department of Hepatic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China. xiajinglin@fudan.edu.cn
Wang
Yao-Hui
YH
Xia
Jing-Lin
JL
Ge
Ning-Ling
NL
Chen
Yi
Y
Ye
Sheng-Long
SL
D016461:Chemoembolization, Therapeutic; D004279:DNA, Viral / Q000097:blood*; D005260:Female; D006509:Hepatitis B / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000235:genetics*; D006801:Humans; D008111:Liver Function Tests; D008113:Liver Neoplasms / Q000097:blood* / Q000628:therapy* / Q000821:virology; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D000509:alpha-Fetoproteins / Q000378:metabolism
D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens; D000509:alpha-Fetoproteins